Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 12, 2015, Pages 1739-1747

  Verdoia, Monica ^a   Pergolini, Patrizia ^a   Rolla, Roberta ^a   Nardin, Matteo ^a   Barbieri, Lucia ^a   Schaffer, Alon ^a   Bellomo, Giorgio ^a   Marino, Paolo ^a   Suryapranata, Harry ^b   De Luca, Giuseppe ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

clopidogrel; coronary artery disease; dual antiplatelet therapy; high residual platelet reactivity; mean platelet volume; platelet aggregation; platelet volume; ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; CORONARY ARTERY DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION ASSAY; PLATELET REACTIVITY; PREVALENCE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE VOLUME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING PARAMETERS; DRUG COMBINATION; DRUG EFFECTS; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; THROMBOCYTE;

ACUTE CORONARY SYNDROME; ADENOSINE; AGED; ASPIRIN; BLOOD PLATELETS; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MEAN PLATELET VOLUME; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; TICLOPIDINE;

EID: 84937681393     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1056151     Document Type: Article

References (58)

1. Clark MG, Beavers C, Osborne J. Managing the acute coronary syndrome patient: Evidence based recommendations for anti-platelet therapy. Heart Lung 2015
2. De Luca G, Suryapranata H. Recent advances in optimal adjunctive antithrombotic therapy in STEMI patients undergoing primary angioplasty: an overview. Curr Vasc Pharmacol 2014
3. Authors/Task Force members. Windecker S, Kolh P, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The task force on myocardial revascularization of the european society of cardiology (ESC) and the european association for cardiothoracic surgery (EACTS) developed with the special contribution of the european association of percutaneous cardiovascular interventions (EAPCI). Eur Heart J 2014; 35(37): 2541-619
4. Verdoia M, Schaffer A, Barbieri L, et al. Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-Analysis of randomized trials. J Cardiovasc Pharmacol 2014; 63(4): 339-50
5. Mayer K, Bernlochner I, Braun S, et al. Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry. J Am Coll Cardiol 2014; 64(9): 863-71
6. Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-Treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62(24): 2261-73
7. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 2005; 45(8): 1157-64
8. Parodi G, Bellandi B, Comito V, et al. Residual platelet reactivity and outcomes with 5 mg prasugrel therapy in elderly patients undergoing percutaneous coronary intervention. Int J Cardiol 2014; 176(3): 874-7
9. Parodi G, Bellandi B, Venditti F, et al. Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel. Am J Cardiol 2012; 109(2): 214-18
10. Alexopoulos D, Xanthopoulou I, Storey RF, et al. Platelet reactivity during ticagrelor maintenance therapy: a patientlevel data meta-Analysis. Am Heart J 2014; 168(4): 530-6
11. Chu SG, Becker RC, Berger PB, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-Analysis. J Thromb Haemost 2010; 8: 148-56
12. Martin JF, Trowbridge EA, Salmon G, Plumb J. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res 1983; 32: 443-60
13. Goncalves SC, Labinaz M, Le May M, et al. Usefulness of mean platelet volume as a biomarker for long-Term outcomes after percutaneous coronary intervention. Am J Cardiol 2011; 107(2): 204-9
14. Lai HM, Xu R, Yang YN, et al. Association of mean platelet volume with angiographic thrombus burden and short-Term mortality in patients with stsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Catheter Cardiovasc Interv 2015
15. Kaya Z, Günebakmaz O, Yildiz A, et al. Mean platelet volume is not associated with coronary slow flow: A retrospective cohort study. Anadolu Kardiyol Derg 2015; 15(1): 18-24
16. Jakl M, Sevcik R, Ceral J, et al. Mean platelet volume and platelet count: overlooked markers of high on-Treatment platelet reactivity and worse outcome in patients with acute coronary syndrome. Anadolu Kardiyol Derg 2014; 14(1): 85-6
17. Beyan C, Kaptan K, Irfan A. Platelet count, mean platelet volume, platelet distribution width, and plateletcrit do not correlate with optical platelet aggregation responses in healthy volunteers. J Thromb Thrombolysis 2006; 22: 161-4
18. De Luca G, Secco GG, Santagostino M, et al. Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. Nutr Metab Cardiovasc Dis 2012; 22: 426-33
19. De Luca G, Venegoni L, Iorio S, et al. Platelet distribution width and the extent of coronary artery disease: results from a large prospective study. Platelets 2010; 21: 508-14
20. Verdoia M, Pergolini P, Camaro C, et al. Novara AtherosclerosisStudy Group (NAS). PlA(1)/PlA(2) polymorphism does not influence response to GpIIb-IIIa inhibitors in patients undergoing coronary angioplasty. Blood Coagul Fibrinolysis 2013; 24: 411-18
21. Vidali M, Rolla R, Parrella M, et al. Role of the laboratory in monitoring patients receiving dual antiplatelet therapy. Int J Lab Hematol 2012; 34: 484-94
22. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-Treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-33
23. Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol 2015; 12(1): 30-47
24. De Luca G, Dirksen MT, Spaulding C, et al. Time course, predictors and clinical implications of stent thrombosis following primary angioplasty. Insights from the DESERT cooperation. Thromb Haemost 2013; 110(4): 826-33
25. Bortnick AE, Epps KC, Selzer F, et al. Five-year follow-up of patients treated for coronary artery disease in the face of an increasing burden of co-morbidity and disease complexity (from the NHLBI Dynamic Registry). Am J Cardiol 2014; 113: 573-9
26. De Luca G, Bellandi F, Huber K, et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-Abciximab long-Term results (Egypt-ALT) cooperation: individual patient's data meta-Analysis. J Thromb Haemost 2011; 9(12): 2361-70
27. De Luca G, Navarese EP, Cassetti E, et al. Meta-Analysis of randomized trials of glycoprotein IIb/IIIa inhibitors in high-risk acute coronary syndromes patients undergoing invasive strategy. Am J Cardiol 2011; 107(2): 198-203
28. De Luca G, Gibson CM, Bellandi F, et al. Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors. Atherosclerosis 2009; 207(1): 181-5
29. Rang-e G, Yayehd K, Belle L, et al. Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY). Arch Cardiovasc Dis 2014; 107(4): 225-35
30. Darlington A, Tello-Montoliu A, Rollini F, et al. Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease. Thromb Haemost 2014; 111(2): 258-65
31. Wallentin L, Becker R.C, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57
32. Parodi G, Valenti R, Bellandi B, et al.comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013; 61: 1601-6
33. Ibrahim K, Christoph M, Schmeinck S, et al. High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation 2014; 85: 649-56
34. Jakubowski JA, Thompson CB, Vaillancourt R, et al. Arachidonic acid metabolism by platelets of differing size. Br J Haematol 1983; 53: 503-11
35. Khaspekova SG, Ziuriaev IT, Iakushkin VV, et al. Mean platelet volume: interactions with platelet aggregation activity and glycoprotein IIb-IIIa and Ib expression levels. Biomed Khim 2014; 60(1): 94-108
36. Coban E, Bostan F, Ozdogan M. The mean platelet volume in subjects with impaired fasting glucose. Platelets 2006; 17: 67-9
37. Coban E, Ozdogan M, Yazcioglu G, Akcit F. The mean platelet volume inpatients with obesity. Int J Clin Pract 2005; 59: 981-2
38. Nadar SK, Blann AD, Kamath S, et al. Platelet indexes in relation to target organ damage in high-risk hypertensive patients A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Am Coll Cardiol 2004; 44: 415-22
39. Lippi G, Meschi T, Borghi L. Mean platelet volume increases with aging in a large population study. Thromb Res 2012; 129: e159-60
40. Huczek Z, Kochman J, Filipiak KJ, et al. Mean platelet volume on admission predicts impaired reperfusion and longterm mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol 2005; 46(2): 284-90
41. De Luca G, Verdoia M, Cassetti E, et al. Mean platelet volume is not associated with platelet reactivity and the extent of coronary artery disease in diabetic patients. Blood Coagul Fibrinolysis 2013; 24(6): 619-24
42. Verdoia M, Camaro C, Barbieri L, et al. Mean platelet volume and the risk of periprocedural myocardial infarction in patients undergoing coronary angioplasty. Atherosclerosis 2013; 228(1): 136-41
43. De Luca G, Santagostino M, Secco GG, et al. Mean platelet volume and the extent of coronary artery disease: results from a large prospective study. Atherosclerosis 2009; 206(1): 292-7
44. Tavil Y, Sen N, Yazici HU, et al. Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease. Thromb Res 2007; 120: 245-50
45. Higaki T, Kurisu S, Watanabe N, et al. Influence of dual antiplatelet therapy on mean platelet volume in patients with coronary artery disease undergoing percutaneous coronary intervention. Heart Vessels 2014
46. Asher E, Fefer P, Shechter M, et al. Increased mean platelet volume is associated with non-responsiveness to clopidogrel. Thromb Haemost 2014; 112(1): 137-41
47. Kubica A, Kasprzak M, Siller-Matula J, et al. Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction. Eur J Pharmacol 2014; 742: 47-54
48. Kim YG, Suh JW, Yoon CH, et al. Platelet volume indices are associated with high residual platelet reactivity after antiplatelet therapy in patients undergoing percutaneous coronary intervention. J Atheroscler Thromb 2014; 21(5): 445-53
49. Shah B, Valdes V, Nardi MA, et al. Mean platelet volume reproducibility and association with platelet activity and antiplatelet therapy. Platelets 2014; 25(3): 188-92
50. Grove EL, Hvas AM, Mortensen SB, et al. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 2011; 9(1): 185-91
51. Smith NM, Pathansali R, Bath PM. Altered megakaryocyte-platelet-haemostatic axis in patients with acute stroke. Platelets 2002; 13(2): 113-20
52. Senaran H, Ileri M, Altinbas' A, et al. Thrombopoietin and mean platelet volume in coronary artery disease. Clin Cardiol 2001; 24(5): 405-8
53. Uzel H, Ozpelit E, Badak O, et al. Diagnostic accuracy of mean platelet volume in prediction of clopidogrel resistance in patients with acute coronary syndrome. Anadolu Kardiyol Derg 2014; 14(2): 134-9
54. Coban E, Afacan B. The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment. Platelets 2008; 19: 111-14
55. Kurisu S, Watanabe N, Ikenaga H, et al. Increased mean platelet volume in patients with coronary artery disease and its seasonal variation. Int J Cardiol 2014; 172(1): e159-61
56. Guo LZ, Kim MH, Jin CD, et al.comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects. Platelets 2014; 2: 1-7
57. Siller-Matula JM, Gruber C, Francesconi M, et al. The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention. Clin Sci (Lond) 2015; 128(2): 121-30
58. CURRENT-OASIS 7 Investigators. Mehta SR, Bassand JP, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363(10): 930-42